Evogene (NASDAQ:EVGN – Get Free Report) is scheduled to announce its earnings results before the market opens on Thursday, November 21st. Persons that wish to listen to the company’s earnings conference call can do so using this link.
Evogene (NASDAQ:EVGN – Get Free Report) last released its earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.94). The company had revenue of $0.91 million during the quarter. Evogene had a negative return on equity of 72.33% and a negative net margin of 210.26%.
Evogene Stock Down 2.9 %
NASDAQ:EVGN opened at $1.68 on Tuesday. The company has a market cap of $9.02 million, a P/E ratio of -0.44 and a beta of 1.43. The firm’s 50 day moving average is $2.49 and its two-hundred day moving average is $4.59. Evogene has a fifty-two week low of $1.66 and a fifty-two week high of $10.40.
Analyst Upgrades and Downgrades
View Our Latest Analysis on EVGN
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Featured Stories
- Five stocks we like better than Evogene
- How to Calculate Options Profits
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Applied Materials Market Capitulates: Now is the Time to Buy
- What Are Dividends? Buy the Best Dividend Stocks
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.